AKAleksey V. Klimov

Aleksey V. Klimov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Aleksey V. Klimov has a total of 137 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Optimization of Response Dynamics Assessment for Targeted ¹⁷⁷Lu-PSMA Radioligand Therapy Using PET/CT, PSA, and SPECT/CT

    by A. V. Parnas, A. S. Krylov, A. V. Filimonov, V. V. Solomyany, V. S. Ilyakov, O. D. Baranova, A. A. Li, A. V. Klimov, А. В. Парнас, А. С. Крылов, et al.

    Purpose : To optimize the evaluation of response dynamics during PSMA-targeted radioligand therapy (RLT) ¹⁷⁷Lu-PSMA based on a comprehensive analysis of prostate-specific antigen (PSA), post-therapeutic single-photon emission computed tomography/ computed tomography (SPECT/CT), and positron emission tomography/computed tomography (PET/CT) with ¹⁸F-PSMA-1007 in patients with metastatic castration-resistant prostate cancer (mCRPC). Material and methods : A retrospective single-center study was conducted, including 78 patients with mCRPC who received 2 to 6 cycles of ¹⁷⁷Lu-PSMA-617 therapy. Monitoring included three levels: PSA dynamics (before each cycle), post-therapeutic SPECT/ CT (24 hours after each administration), and PET/CT with ¹⁸F-PSMA-1007 (baseline and after 2, 4, and 6 cycles). The dynamics of radiopharmaceutical uptake, SUV max values, and concordance between methods were assessed. The primary endpoint was progression-free survival (PFS) assessed by PET/CT. Results : The median PFS by PET/CT in the overall cohort was 9 months. Stratified by PET/CT dynamics after 2 cycles, median PFS was: positive dynamics — 14 months, divergent — 8 months, negative — 5 months (p30 % reduction in SUV max in bone lesions on SPECT/CT after the 1st cycle was associated with longer PFS (13.5 months vs. 5.5 months; p < 0.001). Concordance between PSA and PET/ CT was moderate (κ=0.44), with discordance observed in 17.9 % of cases. The highest concordance was between SPECT/CT and PET/ CT (κ=0.68-0.70). PSMA-negative progression was detected in 5 patients (6.4 %), with 4 of them showing decreasing or stable PSA levels. A >30 % reduction in SUV max in bone lesions on SPECT/CT after the 1st cycle was associated with longer PFS (13.5 months vs. 5.5 months; p < 0.001). No grade ≥3 adverse events were recorded. Conclusion : Combined monitoring (PSA + SPECT/CT after each cycle + PET/CT with ¹⁸F-PSMA-1007 every 2 cycles) is optimal for response assessment during ¹⁷⁷Lu-PSMA therapy. Isolated PSA assessment is insufficient due to high discordance with imaging methods. Post-therapeutic SPECT/CT allows outcome prediction, while PET/CT is essential for detecting PSMA-negative progression and making decisions on therapy continuation or cessation. The proposed three-level approach enables timely treatment individualization.

  • Open Access

    Evolution of darolutamide evidence base: review of new data from international congresses and their role in personalization of systemic therapy selection

    by V. B. Matveev, Матвеев В. Б., Aleksey V. Klimov, Климов Алексей Вячеславович, N. D. Novichkov, Новичков Н. Д.

    Prostate cancer remains one of the leading causes of cancer morbidity and mortality among men worldwide. Over the past decade, the approaches to systemic therapy of advanced prostate cancer have undergone fundamental changes. While androgen-deprivation therapy as monotherapy was previously considered the standard of care, the accumulated body of evidence now strongly supports the need for early treatment intensification using androgen signaling inhibitors and/or docetaxel, as well as their combinations. This strategy significantly improves disease control and extends patient survival. Among second-generation androgen receptor inhibitors, darolutamide holds a distinct position due to its unique chemical structure, which provides high selectivity, minimal blood–brain barrier penetration, and a favorable drug–drug interaction profile. The efficacy and safety of darolutamide have been confirmed in several large-scale international phase III trials encompassing various stages of the disease – from non-metastatic castration-resistant to metastatic hormone-sensitive prostate cancer – both in combination with androgen-deprivation therapy and as part of triplet therapy with docetaxel. However, no matter how robust the evidence from randomized registration trials may be, they cannot provide exhaustive answers to all questions encountered in routine clinical practice. Strict patient selection criteria, fixed treatment regimens, and predefined endpoints limit the generalizability of results to the broader patient population. The ARASAFE, ARASEC, and ARACOG studies, the results of which were presented at major international congresses in 2026, are designed to address these gaps. The aim of this review is to summarize and analyze the data from these studies, define their place, and elucidate their role in facilitating the transition toward a personalized model of systemic therapy selection for patients with advanced prostate cancer.

  • Renal Oncocytoma — Multifaces Appearances

    by N. Ts.‑D. Drobot, X. A. Romanova, E. S. Topalov, S. D. Beghanova, A. V. Klimov, B. M. Medvedeva, A. B. Lukianchenko

    Introduction : The effectiveness of adjuvant radiation therapy used to consolidate the effect of chemotherapy in patients with Purpose : To familiarize readers with the diverse imaging features of renal oncocytomas as seen on 4-phase CT/MRI contrast-enhanced study. Materials and methods : This article is based on one of the largest clinical data, reflecting the wide variety of imaging features of renal oncocytoma in 61 patients who underwent preoperative 4-phase CT/MRI contrast-enhanced study of the abdomen, followed by surgical intervention (resection or nephrectomy) and morphological examination of the resected specimens. Results : The significant diversity in the imaging patterns of oncocytomas depends on the heterogeneity of their morphological structure: marked differences in tumor cellularity, the volume of stroma, and the presence of hemorrhagic and/or cystic elements. This is why their imaging manifistations can overlap with the features of various types of renal cell carcinoma (clear cell, chromophobe cell, etc.), which significantly complicates the accurate preoperative diagnosis of oncocytoma using standard imaging methods (ultrasound, CT, MRI). The well-known and characteristic oncocytoma’s pattern “a spoke-wheel-like enhancement” we observed in only 4 of 61 patients. Conclusion : Differential diagnosis between oncocytoma and renal cell carcinoma based on CT/MRI findings can be extremely difficult in most cases, but is still possible in a few patients.

  • Open Access

    dd-MVAC as neoadjuvant chemotherapy for muscle-invasive bladder cancer: a single-center study

    by Tatiana E. Tikhomirova, A. Yu. Anokhin, E. R. Israelyan, А. N. Lud, S. L. Gutorov, N. L. Vashakmadze, G. A. Arakelyan, A. V. Klimov, A. A. Rumyantsev, V. B. Matveev, et al.

    Aim. To evaluate the efficacy, safety, and feasibility of dd-MVAC (methotrexate, vinblastine, doxorubicin, cyclophosphamide) chemotherapy in real-world clinical practice. Materials and methods. Patients were enrolled between September 2022 and May 2025. They were scheduled to receive six cycles of neoadjuvant dd-MVAC chemotherapy, supported by granulocyte colony-stimulating factor from day 4 to day 9 of each cycle, repeated every two weeks. Eligible patients had urothelial bladder cancer staged as cT2–4a, N0–3, M0, with creatinine clearance of ≥50 mL/min. The primary endpoint was the pathological complete response (pCR) rate. Secondary endpoints included toxicity, the number of treatment cycles completed, and pathological response. Results. The study included 40 patients. Of these, 87 % (n = 35) completed six cycles of dd-MVAC, while 8 % (n = 3) and 5 % (n = 2) completed five and four cycles, respectively. Full protocol drug doses were administered to 57 % of patients (n = 23), while a 15 % dose reduction was required in 43 % (n = 17). The majority of these dose reductions (59 %, n = 10) were implemented after the fifth cycle. The most frequent grade 3 adverse events (per Common Terminology Criteria for Adverse Events (CTCAE) v.5.0) were hematological: neutropenia in 40 % (n = 16), anemia in 10 % (n = 4), and thrombocytopenia in 10 % (n = 4). One fatal case of febrile neutropenia occurred. The most common grade 1–2 adverse event was asthenia reported in 80 % (n = 32) of patients. Surgical treatment was performed in 80 % (n = 32) of the cohort. Cystectomy was conducted in 91 % (n = 29) of these surgical patients, while organ-preserving surgery was performed in 9 % (n = 3). A complete pathological response (ypT0pN0) was achieved in 53 % (n = 17) of surgically treated patients, and downstaging to ypT3pN0 was observed in 9 % (n = 3). Disease stabilization was reported in the remaining 38 % (n = 12). No significant decline in renal function was observed; median glomerular filtration rate was 80.4 mL/min/1.73 m2 pre-treatment and 89.1 mL/min/1.73 m2 post-treatment. Conclusion. The dd-MVAC regimen is an effective and feasible neoadjuvant therapy for muscle-invasive bladder cancer, enabling the majority of patients to complete the full preoperative course of chemotherapy.

  • Endosalpingiosis of the bladder. Clinical observation and literature analysis

    by K. A. Turupaev, D. D. Ladyko, A. K. Tsutsaev, A. V. Klimov, K. M. Figurin, V. B. Matveev

    We present a rare clinical observation of histologically confirmed endosalpingiosis of the bladder in a female patient aged 44 years who underwent combination treatment. This observation is the 8th documented case of isolated endosalpingiosis of the bladder in the world. The article demonstrates the rarity of endosalpingiosis of the bladder, complexity of differential diagnosis of this disease, and the necessity of comprehensive examination with mandatory accurate tumor histogenesis prior to determination of treatment tactics in patients with bladder neoplasms.

  • Open Access

    Combination of lenvatinib and pembrolizumab in treatment of patients with metastatic renal cell carcinoma and factors of poor prognosis

    by A. V. Klimov, A. O. Karyakin, N. Ts. Drobot, E. O. Gazaryan, R. M. Kabardaev, A. K. Valiev, V. B. Matveev, S. V. Averianova

    Renal cell carcinoma (RCC) are among the most frequently diagnosed types of cancer in the world. Despite improvements in diagnostics in the recent years, every third patient with RCC is still diagnosed at the metastatic stage, which explains high mortality rates with this pathology. RCC is a heterogeneous disease. At the stage of metastatic process, factors including presence and site of metastases, prior nephrectomy before systemic therapy, and sarcomatoid differentiation based on the pathomorphological study are most important in determining treatment tactics.In the era of cytokine therapy, patients with metastases were treated with cytoreductive nephrectomy as a first step, as demonstrated in the SWOG and EORTC trials. Currently, the National Comprehensive Cancer Network (NCCN) Guidelines, European Society for Medical Oncology (ESMO) Guidelines, and American Urological Association (AUA) Guidelines suggest a more selective approach to cytoreductive nephrectomy in patients with metastatic RCC and selection of patients for surgery according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) criteria. And for poor prognosis group, preference should be given primarily to dual immune or immune-targeted systemic therapy. Surgical intervention is reserved for patients with not more than 3 factors, with “low metastatic load”, and good performance status.This publication describes a clinical case of successful treatment of a 58-year-old patient with metastatic RCC (T3bN1M1) and poor prognosis according to the IMDC criteria. The patient had no prior history of nephrectomy and presented with a venous tumor thrombus of the right renal vein and the inferior vena cava up to the level of the caval porta, along with metastases to the liver and the 10th thoracic vertebra.The combination of lenvatinib and pembrolizumab was selected as first-line therapy and administered from February 2023 to March 2025 (25 months of treatment).After 3 months of lenvatinib plus pembrolizumab treatment, the tumor thrombus showed reduction (began to be washed by blood), and disease regression was reported in the form of a 60 % reduction in target lesions per the RECIST 1.1 (Response Evaluation Criteria in Solid Tumors) criteria. Most notably, the liver metastasis demonstrated a remarkable decrease from 7 cm to 2 cm (78 % reduction), which was achieved with the therapy conducted. The tumor of the right kidney exhibited a 50 % size reduction (from 10 cm to 5 cm), accompanied by decreased contrast enhancement in the aortic phase on imaging.

  • Open Access

    TIP regimen (paclitaxel, ifosfamide, cisplatin) in nonseminomatous germ cell tumors with poor-prognosis and unfavorable decline of serum tumor markers: final results

    by E. R. Israelyan, A. A. Tryakin, A. A. Rumyantsev, M. Yu. Fedyanin, P. V. Kononets, S. S. Gerasimov, V. B. Matveev, M. I. Volkova, A. V. Klimov, A. I. Semenova, et al.

    Background: Patients with germ cell tumors (GCTs) and poor-prognosis demonstrate unsatisfactory oncological outcomes, with a one-year progression-free survival (PFS) rate of approximately 50 %. We hypothesized that switching the chemotherapy regimen to TIP (paclitaxel, ifosfamide (mesna), cisplatin) in cases of unfavorable decline of serum tumor markers (STMs) after the first cycle of BEP (bleomycin, etoposide, cisplatin) could improve treatment outcomes in this subgroup of patients.Materials and methods: A multicenter, prospective, non-randomized phase II study included patients with nonseminomatous GCTs and poor-prognosis according to IGCCCG. All patients received the first cycle of chemotherapy in BEP regimen. Patients with an unfavorable decline of STMs subsequently received 4 cycles of TIP regimen (paclitaxel 120 mg / m² on days 1 and 2 + ifosfamide 1500 mg / m² on days 2–5 (+ mesna) + cisplatin 25 mg / m² on days 2–5 + G-CSF). In the presence of residual tumors larger than 1 cm and the technical feasibility of removal, surgical treatment was performed. The primary endpoint was one-year PFS.Results: From 2017 to 2023, 34 patients were included in the study. Enrollment was prematurely closed due to an extremely low likelihood of achieving the primary endpoint. One-year PFS and overall survival (OS) were 57.1 % and 74.4 %, respectively. The favorable response rate (complete response + partial response with normalization STM) was observed in 55,8 % of patients. Disease progression was observed in 21 patients, with the central nervous system being the first site of progression in 8 (37 %) of them. Surgical treatment was performed in 16 patients, with viable tumor obtained in 4 patients. Conducting the first cycle in a “stabilization» mode for ultra-high-risk patients did not affect PFS (p = 0.28) or OS (p = 0.434). The toxicity profile of the TIP regimen was acceptable.Conclusion: Switching from BEP to TIP for patients with nonseminomatous GCTs and an unfavorable decline of STMs did not demonstrate efficacy. Further exploration of alternative therapeutic approaches is needed to improve treatment outcomes.

  • Open Access

    Numerical simulation of thermophysical processes in the bubble as an element of a masking curtain

    by Alexej Klimov, Oleksandr Isakov, Anton Pashuba, Oleksandr Kyprinenko, Олексій Клімов, Олександр Ісаков

    The movement of a bubble in an air stream with the consideration of the heat exchange process between the air, the bubble shell and the heated air inside the bubble was numerically investigated. Numerical modeling was carried out in the Ansys Fluent software product. It was assumed that the injection of the bubble takes place in the air flow, which has a speed of 3 m/s, and the air temperature is 293 K. The calculation was carried out for the diameters of the bubbles, which were equal to 3 mm and 5 mm. The thickness of the bubble shell was equal to 1 μm. It was assumed that at the time of injection of the bubble into the air flow, the initial temperature of the heated air, which is filled with the bubble, exceeds the temperature of the surrounding air in the first variant by 10 K and in the second variant by 30 K. The velocity field of the air flow that occurs inside the bubble during its external flow with a speed of 3 m/s and when the external air is stationary. The bubble surface temperature and air velocity vector field are calculated. Based on the analysis of the simulation results, it was determined that achieving the volatility of the bubble by heating the gas is not expedient due to the short air cooling time, which in the calculated versions did not exceed 250 ms. Therefore, the most effective method for achieving bubble volatility is determined in this paper. Based on the above, we come to the general conclusion that the filling should be with a gas of the density that is less than the density of air under the same thermodynamic conditions. These processes should form the basis of a mechanism that will ensure thermal reconnaissance protection of armoured weapons. This function is most effective when the enemy uses night vision devices. This area should take constant development steps to counteract the enemy's reconnaissance tasks. The material part of the study (gas and liquid) should be studied in interaction and subject to experimental investigation. These actions are aimed at achieving maximum effect.

  • Open Access

    The combination of lenvatinib and pembrolizumab in the treatment of patients with metastatic kidney cancer and factors of poor prognosis: experience of clinics in Moscow: A prospective observational study

    by Ilya A. Pokataev, Daniil L. Stroyakovskiy, Mikhail Y. Fedyanin, Liudmila G. Zhukova, Olesia A. Stativko, Irina I. Andreyashkina, Maria I. Volkova, Mikhail V. Volkonskiy, Natalya I. Polshina, Ekaterina V. Kotova, et al.

    Background. Combination therapy is the standard of care for intermediate and poor prognosis metastatic renal cell carcinoma. In the IMDC prognostic classification, tumor stage and histological type are not considered due to the lack of independent impact on overall survival. The CLEAR study demonstrated the efficacy of lenvatinib and pembrolizumab combination in long-term treatment outcomes, including overall survival in poor prognosis compared to sunitinib. The KEYNOTE-B61 study demonstrated high efficacy of this combination in patients with non-clear cell renal cell carcinoma. Aim. To evaluate the efficacy of the combination of lenvatinib and pembrolizumab in patients with high tumor burden and non-clear cell histotypes. Materials and methods. This prospective observational study included 54 patients with metastatic renal cell carcinoma who received a combination of lenvatinib and pemrolizumab in the first line between 2022 and May 2024 in oncology clinics of the Moscow Department of Health. Clear cell histotype was represented in 79.6% of cases, 14.8% had papillary cancer, and 5.6% of patients had chromophobe cancer. The primary endpoint was the objective response rate. Results. The objective response was assessed in 50 patients. The objective response rate was 38%, including 2% complete response according to RECIST 1.1, disease progression was in 8% of patients. The median depth of response was -25% (from -100% to +28). The median time to response was 12.4 weeks (1.1–38.3). Conclusion. The efficacy of the combination of lenvatinib and pembrolizumab in real-life clinical practice outside the inclusion criteria of the CLEAR study is clinically significant and allows us to expect improvement even in patients with a large volume of metastatic process and non-clear cell histotype, but the expected benefit in patients with unsatisfactory somatic status remains disputed.


  • Tumor of the Renal Pelvis Accompanying Coral Nephrolithiasis

    by I. S. Grashchenko, N. Ts. Drobot, A. V. Klimov, O. A. Halmurzaev, S. D. Bejanova, B. M. Medvedeva, K. A. Romanova, E. S. Kolobanova, M. G. Lapteva, A. B. Lukianchenko

    Cancer of the renal pelvis, in particular the squamous cell form, is an extremely rare neoplasm of this localization. Chronic inflammation is thought to be a risk factor for this disease due to the presence of stones in the collecting system. Having no specific clinical manifestations, this tumor is often an incidental finding identified during examination of patients for other reasons.This article presents a clinical case of squamous cell carcinoma of the renal pelvis in a patient with a long course of urolithiasis and the presence of staghorn stones, complicated by a kidney abscess diagnosed by CT and MRI.